Get the Stockscreener App
114.46
0.03%
-0.0492
Arcellx Inc stock is traded at $114.46, with a volume of 153.50K.
It is down -0.03% in the last 24 hours and up +63.07% over the past month.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.
See More
Previous Close:
$114.51
Open:
$114.42
24h Volume:
153.50K
Relative Volume:
0.08
Market Cap:
$6.69B
Revenue:
$22.29M
Net Income/Loss:
$-228.93M
P/E Ratio:
-28.23
EPS:
-4.0547
Net Cash Flow:
$-212.59M
1W Performance:
+0.07%
1M Performance:
+63.07%
6M Performance:
+49.80%
1Y Performance:
+57.38%
1-Day Range:
$114.40
$114.62
1-Week Range:
$114.26
$114.62
52-Week Range:
$47.86
$114.80
Arcellx Inc Stock (ACLX) Company Profile
Name
Arcellx Inc
Sector
Industry
Phone
240-327-0603
Address
800 BRIDGE PARKWAY, REDWOOD CITY
Compare ACLX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACLX
Arcellx Inc
|
114.46 | 6.70B | 22.29M | -228.93M | -212.59M | -4.0547 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.68 | 118.41B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
763.70 | 80.02B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
713.26 | 43.52B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.00 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
288.99 | 32.13B | 5.36B | 287.73M | 924.18M | 2.5229 |
Arcellx Inc Stock (ACLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-12-26 | Downgrade | Rothschild & Co Redburn | Buy → Neutral |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-22-25 | Initiated | Wells Fargo | Overweight |
| Nov-18-25 | Initiated | Wolfe Research | Peer Perform |
| Oct-16-25 | Initiated | Stifel | Buy |
| Jun-17-25 | Initiated | Citigroup | Buy |
| Oct-08-24 | Initiated | Redburn Atlantic | Buy |
| Sep-03-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| Mar-07-24 | Initiated | Morgan Stanley | Overweight |
| Jan-04-24 | Reiterated | Needham | Buy |
| Dec-19-23 | Initiated | Scotiabank | Sector Outperform |
| Oct-30-23 | Initiated | TD Cowen | Outperform |
| Oct-17-23 | Initiated | UBS | Buy |
| May-18-23 | Initiated | Truist | Buy |
| Apr-14-23 | Initiated | Robert W. Baird | Outperform |
| Mar-14-23 | Initiated | Stifel | Buy |
| Feb-13-23 | Initiated | H.C. Wainwright | Buy |
| Dec-13-22 | Resumed | BofA Securities | Buy |
| Oct-31-22 | Initiated | Guggenheim | Buy |
| Oct-27-22 | Initiated | Needham | Buy |
| Jul-20-22 | Initiated | Canaccord Genuity | Buy |
| Mar-01-22 | Initiated | BofA Securities | Buy |
| Mar-01-22 | Initiated | SVB Leerink | Outperform |
View All
Arcellx Inc Stock (ACLX) Latest News
Gilead Sciences at Barclays: CFO touts YEZTUGO launch, Arcellx deal and “long cycle” growth - MarketBeat
Arcellx and Aardvark Therapeutics Compared - National Today
This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal - The Motley Fool
Arcellx, Inc. $ACLX Position Lifted by HighVista Strategies LLC - MarketBeat
Bamco Inc. NY Increases Stake in Arcellx, Inc. - National Today
Bamco Inc. NY Has $45.17 Million Stake in Arcellx, Inc. $ACLX - MarketBeat
Gilead Sciences to buy Arcellx in deal valued at $7.8 billion - MSN
Integral Health Asset Management LLC Invests $12.32 Million in Arcellx, Inc. $ACLX - MarketBeat
Arcellx Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Arcellx, Inc.ACLX - Business Wire
Gilead Sciences to buy Arcellx in deal worth up to $7.8B - MSN
Shareholder Alert: The Ademi Firm Investigates Whether Arcellx Inc. Is Obtaining a Fair Price for Its Public Shareholders - 富途牛牛
Will GILD's Move to Acquire ACLX Boost Its Cell Therapy Franchise? - sharewise.com
Short Interest in Arcellx, Inc. (NASDAQ:ACLX) Declines By 38.0% - MarketBeat
Victory Capital Management Inc. Has $14.13 Million Stock Position in Arcellx, Inc. $ACLX - MarketBeat
Gilead’s US$7.8b Arcellx Deal Deepens Cell Therapy Diversification - simplywall.st
Gilead to Acquire Arcellx, Inc. (ACLX) for Up to $7.8 billion - Finviz
Are ACLX, DBRG, AVO, CVGW Obtaining Fair Deals for their Shareholders? - Sahm
Arcellx set to report earnings amid $7.8B Gilead deal - Investing.com
American Century Companies Inc. Has $33.82 Million Position in Arcellx, Inc. $ACLX - MarketBeat
Gilead to buy US biotech Arcellx for up to $7.8 billion - MSN
Blue Owl Capital Holdings LP Buys Shares of 26,823 Arcellx, Inc. $ACLX - MarketBeat
Arcellx (NASDAQ: ACLX) backs $115 cash plus $5 CVR tied to $6B anito-cel sales - Stock Titan
(ACLX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Arcellx Inc share price - Capital.com
Gilead Sciences stock forecast for 2030: Can $7.8B Arcellx deal push GILD to $220 with no patent cliff until 2036? - Traders Union
Arcellx, Inc. (NASDAQ:ACLX) Receives Average Rating of "Hold" from Analysts - MarketBeat
Halper Sadeh LLC is Investigating Whether ACLX, VRE, EHAB are Obtaining Fair Deals for their Shareholders - GlobeNewswire
Top 2 Health Care Stocks That May Crash This QuarterArcellx (NASDAQ:ACLX), Anika Therapeutics (NASDAQ:ANIK) - Benzinga
Multiple Myeloma Market 2026: Gilead Sciences Acquires Arcellx for $7.8B to Control CAR-T Therapy - openPR.com
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Arcellx Inc (ACLX), Alkermes (ALKS) and Progyny (PGNY) - The Globe and Mail
Arcellx Inc stock hits all-time high at 114.27 USD - Investing.com Australia
Are ACLX, VRE, LSF Obtaining Fair Deals for their Shareholders? - Stock Titan
Gilead Sciences’ Yeztugo Revenue Is Set to Jump 400%: Here’s What Comes Next - TIKR.com
Arcellx (NASDAQ:ACLX) Hits New 52-Week HighStill a Buy? - MarketBeat
Arcellx Inc stock hits all-time high at 114.27 USD By Investing.com - Investing.com UK
Arcellx, Inc. (ACLX) Stock Analysis: Navigating Biotech’s Cutting Edge with Strategic Alliances - DirectorsTalk Interviews
Cowen Downgrades Arcellx, Inc. (ACLX) to Hold on March 2, 2026 - Meyka
ACLX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Gilead Sciences Arcellx Deal Deepens Oncology Bet And Tests HIV Reliance - Yahoo Finance
Arcellx stock rating cut to Hold by TD Cowen on Gilead deal - Investing.com India
Arcellx President Sells $10 Million Worth of Shares After Acquisition Announcement - The Globe and Mail
Arcellx President Sells $10M Worth of Shares After Acquisition Announcement - The Globe and Mail
TD Cowen Downgrades Arcellx to Hold From Buy - marketscreener.com
Citigroup Inc. Sells 13,427 Shares of Arcellx, Inc. $ACLX - MarketBeat
TD Asset Management Inc Buys 129,248 Shares of Arcellx, Inc. $ACLX - MarketBeat
Vanguard Group Inc. Sells 37,798 Shares of Arcellx, Inc. $ACLX - MarketBeat
Insider Selling: Arcellx (NASDAQ:ACLX) Insider Sells 89,916 Shares of Stock - MarketBeat
Arcellx CEO Elghandour sells $10.2 million in ACLX stock - Investing.com
Tax-withholding sale by Arcellx (NASDAQ: ACLX) director Elghandour - Stock Titan
Arcellx, Inc. Hits Day High with 77.43% Surge in Stock Price - Markets Mojo
E-Trade Financial (NASDAQ: ACLX) files Form 144 listing 164,548 RSU shares - Stock Titan
Arcellx Inc Stock (ACLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):